Tunlametinib

Tunlametinib is a selective mitogen-activated protein kinase 1 and kinase 2 (MEK1/2) kinase inhibitor, which plays an antitumor role by inhibiting the activity of MEK1/2 kinase. The marketing of this drug provides new treatment options for patients with advanced NRAS-mutant melanoma who fail anti- PD-1/PD-L1 therapy.

Tunlametinib, an antineoplastic agent, is a MEK1/2 inhibitor[1].

MEK1; MEK2

[1] International Nonproprietary Names for Pharmaceutical Substances (INN)
[2] KEAM S J. Tunlametinib: First Approval.[J]. Drugs, 2024: 1005-1010. DOI:10.1007/s40265-024-02072-x.
[3] YAHONG LIU. Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor.[J]. Frontiers in Pharmacology, 2023, 14: 1271268. DOI:10.3389/fphar.2023.1271268.
[4] QIAN ZHAO. Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma.[J]. ACS Applied Energy Materials, 2022: 1039416. DOI:10.3389/fphar.2022.1039416.